Debating Open Access

In the opinion article by Peter Farnham and William R. Brinkley,1 those who advocate open access to science literature were portrayed as launching a "broad-based attack on all business models for scientific publication other than their own." This is an unfortunate characterization. They just propose an alternative that avoids the serious drawbacks of the subscription system.It is beyond dispute, one hopes, that full access for research scientists to the literature is highly desirable. Traditiona

Written byJan Velterop
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

In the opinion article by Peter Farnham and William R. Brinkley,1 those who advocate open access to science literature were portrayed as launching a "broad-based attack on all business models for scientific publication other than their own." This is an unfortunate characterization. They just propose an alternative that avoids the serious drawbacks of the subscription system.

It is beyond dispute, one hopes, that full access for research scientists to the literature is highly desirable. Traditional subscription models make such open access impossible, based as they are on journal subscriptions paid by readers (or, rather more likely, on their behalf by institutions).

For many a researcher this presents a problem. The proposed alternative, whereby the costs of publishing are borne by authors (or, more likely, by their research grants), would make full access feasible. This is not an attack, it is an attempt to solve the problem.

The authors also associate ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies